Biotech Investment Evolution
Zav discusses the historical reluctance of traditional biotech firms to embrace technology, emphasizing the need for organic development rather than superficial integration. Adam highlights the potential for collaboration between innovative funds and established players, while acknowledging that not all firms will align with this forward-thinking approach. The conversation also touches on the shifting investment landscape due to rising interest rates, raising questions about the appetite for high-risk, low-revenue projects.In this clip
From this podcast
Newcomer Podcast
A New Dimension (w/Nan Li, Adam Goulburn, and Zavain Dar)
Related Questions